Trial record 12 of 72 for:    Open Studies | "nutritional support"

Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors (Ketones)

This study is currently recruiting participants. (see Contacts and Locations)
Verified December 2014 by Michigan State University
Sponsor:
Collaborator:
Sparrow Health System
Information provided by (Responsible Party):
Kenneth Schwartz, MD, Michigan State University
ClinicalTrials.gov Identifier:
NCT01535911
First received: February 3, 2012
Last updated: December 15, 2014
Last verified: December 2014
  Purpose

This study will look at the effects, good and/or bad, of treating primary brain cancers with diet therapy using an energy restricted ketogenic diet (ERKD) that uses food. An energy restricted ketogenic diet is a diet designed to keep blood sugars in the low range of normal while at the same time increasing the blood concentration of metabolic break down products called ketones. This diet is currently used to treat children with uncontrollable seizures. This diet is well tolerated by the children with minimal side effects reported after using the diet for years.

  • The main purpose of this study is to find out whether or not the energy restricted ketogenic diet will help patients with primary brain cancer by either decreasing the size of the cancer or by keeping the cancer from growing.
  • Another reason for doing this study is to learn about the side effects associated with the energy restricted ketogenic diet in patients with primary brain cancer.

Condition Intervention
Glioblastoma
Other: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Pilot Study of a Metabolic Nutritional Therapy for the Management of Primary Brain Tumors

Resource links provided by NLM:


Further study details as provided by Michigan State University:

Primary Outcome Measures:
  • MRI imaging will be used to measure changes in brain tumor size. [ Time Frame: 6 weeks after completion of radiation therapy ] [ Designated as safety issue: No ]
    Results of the metabolic therapy will be assessed by comparing MRI images obtained at the beginning of the study with those after completion of radiation therapy and after an additional 6 weeks of metabolic therapy.


Estimated Enrollment: 12
Study Start Date: April 2012
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: November 2015 (Final data collection date for primary outcome measure)
Intervention Details:
    Other: Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)
    Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
    Other Name: Ketogenic diet
Detailed Description:

Summary: The current standard of care for glioblastoma multiforme (GBM), the most common primary brain tumor in adults, includes surgical resection, radiation and chemotherapy. Survival rarely exceeds 18 months. The investigators propose to test the hypothesis that brain tumor cells are unable to utilize ketones as a source of energy when deprived of glucose, due to mitochondrial dysfunction, whereas normal glia and neurons can survive this metabolic stress. A nutritionally adequate but energy restricted, ketogenic diet (ERKD) to deprive brain tumors of energy and resulting in death of glioma cells is promising. ERKD-based therapy to manage brain cancer is both biologically plausible and supported by data in animal models. A multidisciplinary team of oncologists, registered dietitians, and physiologists will implement an ERKD therapy in newly diagnosed GBM subjects. After initial maximal tumor excision, ERKD therapy will be initiated for subjects during a one week inpatient admission to Sparrow Hospital or as a local outpatient and supervised by registered dietitians experienced in implementing this therapy.The ERKD will continue as adjunctive therapy along with radiation therapy and standard of care chemotherapy. The supervised ERKD will continue for an additional 6 weeks after completion of radiation therapy along with the standard of care chemotherapy. The objective of this trial is to determine whether the ERKD decreases tumor size or results in no recurrence in individuals with GBM as measured by serial MRI imaging. Enzymes and signaling pathways that regulate metabolism and cell growth will be assessed in initial and post-ERKD tumors using standard biochemical approaches.

  Eligibility

Ages Eligible for Study:   18 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • Inclusion Criteria:
  • Adult subjects over age 18 with biopsy proven GBM diagnosis
  • Measurable disease after standard therapies
  • Eastern Cancer Oncology Group performance status < or =2; and
  • Life expectancy >3 months.

Exclusion Criteria:

  • Diagnosis of diabetes mellitus that is being treated by medication
  • Concomitant use of glucocorticosteroids
  • Cholecystectomy within 1 year prior to study entry
  • Inability to adhere to or tolerate dietary protocol
  • Active malignancy other than primary brain tumor requiring therapy
  • Participation in an investigational study within 2 weeks prior to study entry; Major co-morbidities such as liver, kidney or heart failure that in the judgment of the investigators would disqualify the subject from the trial
  • Pregnancy
  • Inability to give informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01535911

Contacts
Contact: Kenneth Schwartz, MD 517-975-9547

Locations
United States, Michigan
Michigan State University/Sparrow Hospital Recruiting
E. Lansing, Michigan, United States, 48824
Contact: Ken A. Schwartz, MD    517-353-4811    ken.schwartz@hc.msu.edu   
Contact: Mary M. Noel, PhD    517.884.0451    mary.noel@hc.msu.edu   
Principal Investigator: Ken A Schwartz, MD         
Sponsors and Collaborators
Michigan State University
Sparrow Health System
Investigators
Principal Investigator: Kenneth Schwartz, MD Michigan State University
  More Information

Publications:
Responsible Party: Kenneth Schwartz, MD, Professor, Michigan State University
ClinicalTrials.gov Identifier: NCT01535911     History of Changes
Other Study ID Numbers: 11-452FS
Study First Received: February 3, 2012
Last Updated: December 15, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Michigan State University:
ketogenic diet
brain tumors

ClinicalTrials.gov processed this record on March 26, 2015